Suppression of inflammation and structural damage in experimental arthritis through molecular targeted therapy with PPI-2458

Arthritis and Rheumatism

Volumn 56, Issue 3, 2007, Pages 850-860

  Hannig, Gerhard ^a,b   Bernier, Sylvie G ^a   Hoyt, Jennifer G ^a   Doyle, Beth ^b   Clark, Ed ^b   Karp, Russell M ^b   Lorusso, Jeanine ^b   Westlin, William F ^b  

^a Infinity Pharmaceuticals Inc   (United States)

^b Praecis Pharmaceuticals Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(1 CARBAMOYL 2 METHYLPROPYL)CARBAMIC ACID 5 METHOXY 4 [2 METHYL 3 (3 METHYL BUT 2 ENYL)OXIRANYL] 1 OXA SPIRO[2.5]OCT 6 YL ESTER; CARBOXY TERMINAL TELOPEPTIDE; METHIONINE AMINOPEPTIDASE 2; METHIONYL AMINOPEPTIDASE; PPI 2458; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; INFLAMMATION; JOINT DESTRUCTION; JOINT SWELLING; LEWIS RAT; MORPHOMETRICS; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTECTION; RAT; RHEUMATOID ARTHRITIS; TARSAL JOINT;

AMINOPEPTIDASES; ANIMALS; ARTHRITIS, RHEUMATOID; BONE RESORPTION; CELL DIFFERENTIATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; EPOXY COMPOUNDS; FEMALE; GLYCOPROTEINS; HUMANS; JOINTS; OSTEOCLASTS; PEPTIDOGLYCAN; POLYSACCHARIDES; RATS; RATS, INBRED LEW; SEVERITY OF ILLNESS INDEX; VALINE;

EID: 33947127045     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22402     Document Type: Article

References (46)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Koch AE. Angiogenesis: implications for rheumatoid arthritis [review]. Arthritis Rheum 1998;41:951-62.
3. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001;358: 903-11.
4. Sweeney SE, Firestein GS. Rheumatoid arthritis: regulation of synovial inflammation. Int J Biochem Cell Biol 2004;36:372-8.
5. Goldring SR. Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 2002;14:406-10.
6. Teitelbaum SL. Bone resorption by osteoclasts. Science 2000;289: 1504-8.
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337-42.
8. Gravallese EM, Manning C, Tsay A, Naito A, Pan C, Amento E, et al. Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. Arthritis Rheum 2000;43:250-8.
9. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000;43:2523-30.
10. Wu Y, Liu J, Feng X, Yang P, Xu X, Hsu HC, et al. Synovial fibroblasts promote osteoclast formation by RANKL in a novel model of spontaneous erosive arthritis. Arthritis Rheum 2005;52: 3257-68.
11. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum 2002;46: 328-46.
12. Hofbauer LC, Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004;292:490-5.
13. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.
14. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
15. Griffith EC, Su Z, Turk BE, Chen S, Chang YH, Wu Z, et al. Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 1997; 4:461-71.
16. Sin N, Meng L, Wang MQ, Wen JJ, Bornemann WG, Crews CM. The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 1997;94:6099-103.
17. Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 1998;282:1324-7.
18. Bernier SG, Lazarus DD, Clark E, Doyle B, Labenski MT, Thompson CD, et al. A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci U S A 2004;101:10768-73.
19. Bernier SG, Westlin WF, Hannig G. Fumagillin class inhibitors of methionine aminopeptidase-2. Drugs Future 2005;30:497-508.
20. Datta B, Chakrabarti D, Roy AL, Gupta NK. Roles of a 67-kDa polypeptide in reversal of protein synthesis inhibition in heme-deficient reticulocyte lysate. Proc Natl Acad Sci U S A 1988;85: 3324-8.
21. Arfin SM, Kendall RL, Hall L, Weaver LH, Stewart AE, Matthews BW, et al. Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes. Proc Natl Acad Sci U S A 1995;92: 7714-8.
22. Bradshaw RA. Methionine aminopeptidases and angiogenesis. Essays Biochem 2002;38:65-78.
23. Bernier SG, Taghizadeh N, Thompson CD, Westlin WF, Hannig G. Methionine aminopeptidases type I and type II are essential to control cell proliferation. J Cell Biochem 2005;95:1191-203.
24. Brahn E, Banquerigo ML, Schoettler NR, Lee S. A new angiogenesis inhibitor, PPI-2458: regression of collagen-induced arthritis and prevention of erosions [abstract]. Arthritis Rheum 2001;44 Suppl 9:S271.
25. Brahn E, Schoettler N, Banquerigo ML, Thompson CD. Involution of collagen-induced arthritis with an angiogenesis inhibitor PPI-2458 [abstract]. Arthritis Rheum 2003;48 Suppl 9:S347.
26. O'Byrne EM, Roberts ED, Rubin AS, Blancuzzi V, Wilson D, Hall NR, et al. Lactobacillus casei-induced polyarthritis in Lewis rats: histopathological scoring system for evaluation of anti-rheumatic drugs. Agents Actions 1991;134:239-41.
27. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci U S A 1998;95:15671-6.
28. Chen FH, Thomas AO, Hecht JT, Goldring MB, Lawler J. Cartilage oligomeric matrix protein/thrombospondin 5 supports chondrocyte attachment through interaction with integrins. J Biol Chem 2005;280:32655-61.
29. Lainer DT, Brahn E. New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 2005; 14:1-17.
30. Peacock DJ, Banquerigo ML, Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J Exp Med 1992;173:1135-8.
31. Oliver SJ, Banquerigo ML, Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell Immunol 1994;157:291-9.
32. De Bandt M, Grossin M, Weber AJ, Chopin M, Elbim C, Pla M, et al. Suppression of arthritis and protection from bone destruction by treatment with TNP-470/AGM-1470 in a transgenic mouse model of rheumatoid arthritis. Arthritis Rheum 2000;43:2056-63.
33. Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termungruanglert W, et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin Cancer Res 1997;3:1501-5.
34. Bhargava P, Marshall JL, Rizvi N, Dahut W, Yoe J, Figuera M, et al. A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 1999;5: 1989-95.
35. Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, et al. Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin Cancer Res 2001;7:1198-203.
36. Anandarajah AP, Schwarz EM. Anti-RANKL therapy for inflammatory bone disorders: mechanisms and potential clinical applications. J Cell Biochem 2006;97:226-32.
37. Hasegawa J, Nagashima M, Yamamoto M, Nishijima T, Katsumata S, Yoshino S. Bone resorption and inflammatory inhibition efficacy of intermittent cyclical etidronate therapy in rheumatoid arthritis. J Rheumatol 2003;30:474-79.
38. Mansson B, Carey D, Alini M, Ionescu M, Rosenberg L, Poole AR, et al. Cartilage and bone metabolism in rheumatoid arthritis. J Clin Invest 1995;95:1071-7.
39. Lindqvist E, Eberhardt K, Bendtzen K, Heinegard D, Saxne T. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Ann Rheum Dis 2005;64:196-201.
40. Osterman T, Virtamo T, Lauren L, Kippo K, Pasanen R, Hannuniemi R, et al. Slow-release clodronate in prevention of inflammation and bone loss associated with adjuvant arthritis. J Pharmacol Exp Ther 1997;280:1001-7.
41. Yamane I, Hagino H, Okano T, Enokida M, Yamasaki D, Teshima R. Effect of minodronic acid (ONO-5920) on bone mineral density and arthritis in adult rats with collagen-induced arthritis. Arthritis Rheum 2003;48:1732-41.
42. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002;161: 1419-27.
43. Herrak P, Gortz B, Hayer S, Redlich K, Reiter E, Gasser J, et al. Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor-mediated arthritis. Arthritis Rheum 2004; 50:2327-37.
44. Crnkic M, Mansson B, Larsson L, Geborek P, Heinegard D, Saxne T. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. Arthritis Res Ther 2003;5:R181-5.
45. Wislowska M, Jablonska B. Serum cartilage oligomeric matrix protein (COMP) in rheumatoid arthritis and knee osteoarthritis. Clin Rheumatol 2005;24:278-84.
46. Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002;46:1926-36.